Lyell Immunopharma, Inc. has announced a significant update regarding its ownership structure through a recent Schedule 13G/A filing. The filing reveals that ARCH Venture Fund IX, along with its affiliated entities, holds a substantial 17.4% of the company’s common stock. This development is noteworthy as it underscores the increasing influence of venture capital in the pharmaceutical preparations industry.
Based in South San Francisco, California, Lyell Immunopharma is a company focused on innovative treatments in the pharmaceutical sector, specifically classified under SIC 2834, which pertains to pharmaceutical preparations. The company trades on the Nasdaq under the ticker symbol LYEL. The latest filing, dated November 10, 2026, follows a series of recent filings, including a private placement transaction that occurred on November 4, 2026.
The Schedule 13G/A filing indicates that ARCH Venture Fund IX, L.P. is the record owner of 910,317 shares, while ARCH Venture Fund XIII, L.P. holds 3,747,790 shares. The total beneficial ownership reported by these entities amounts to 5,568,424 shares, reflecting a growing commitment to Lyell Immunopharma.
“The Reporting Persons disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record,” the filing states.
This update may have far-reaching implications for various stakeholders, including existing shareholders, potential investors, and competitors in the pharmaceutical sector. The significant stake held by ARCH Venture Fund IX and its affiliates could influence future strategic decisions at Lyell Immunopharma, potentially steering the company towards new partnerships or product development initiatives.
Looking ahead, it remains to be seen how this ownership change will affect Lyell Immunopharma's operations and its position within the competitive landscape of pharmaceutical preparations. The filing does not specify any immediate next steps or actions resulting from this ownership update.
In summary, the recent Schedule 13G/A filing by Lyell Immunopharma highlights a critical shift in ownership dynamics, reflecting the growing role of venture capital in shaping the future of the pharmaceutical industry.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





